Risk Factors Update Summary

• The company’s total liabilities increased from $470 million to $944 million, indicating significant financial risk. This change might result in increased scrutiny from investors.
• Comprehensive loss attributable to Rafael Holdings, Inc. increased from $2,211 to $33,997. This change might result in significant investor concern regarding financial stability.
• The ongoing war between Israel and Hamas may adversely affect our real estate holdings and operations, potentially leading to a decrease in revenues.
• The Company recorded a full impairment charge of $79 million related to Cornerstone Pharmaceuticals due to negative data events. This significant loss could impact investor confidence and future funding.
• Rafael acquired approximately 67% of Cornerstone's voting interests through the Cornerstone Acquisition, significantly increasing control. This change might result in enhanced operational influence and strategic direction.
• The allowance for doubtful accounts increased from $245 to $279, indicating higher expected credit losses.
• The conversion of $30.6 million of the RFL Line of Credit into 30,080,747 shares of Cornerstone Common Stock represents a recovery of a previously written-off asset.
• The company has added a new risk factor regarding potential regulatory changes affecting operations. This could impact financial performance significantly.
• Cornerstone is obligated to pay annual license maintenance fees of $20,000, escalating to $1,000,000 post-approval. This change might result in significant future financial obligations.
• New regulations by the SEC effective December 18, 2023, require greater cybersecurity disclosures, potentially diverting management's attention.
• The Business Combination is expected to close in the fourth calendar quarter of 2024. This change might result in significant operational shifts for the company.
• Total comprehensive loss attributable to noncontrolling interests rose from $17,746 to $30,595. This change indicates potential risks in managing subsidiary investments.
• The Company resolved to curtail early-stage development efforts, impacting pre-clinical research at Barer Institute. This may affect future project timelines and costs.
• The recent downgrade of Israel's credit rating from A1 to A2 by Moody's could impact our business operations and financial condition.
• The gain on disposal of discontinued operations increased from $1,830 thousand to $6,784 thousand, significantly impacting financial results.
• The acquisition of Cornerstone Pharmaceuticals resulted in an in-process research and development asset of approximately $89,861,000. This significant investment reflects the company's strategic focus on oncology.
• The Company recorded bad debt expense from continuing operations of approximately $20 thousand for 2024, compared to $0 for 2023. This change might result in increased financial scrutiny.
• The definition of liabilities has been updated to include current liabilities, enhancing transparency. This change could impact financial ratios significantly.
• The company increased its ownership interest in Day Three Labs, Inc. from 79% to 84%. This change might result in enhanced control over operations and strategic direction.
• The definition of stock issued during the period now includes shares from Restricted Stock Awards forfeited. This change might influence the understanding of share dilution.
• The company disclosed a new operating lease liability payment due of $3,000,000. This change might result in increased financial obligations.
• The Merger Agreement includes restrictions that may limit our ability to pursue business opportunities, affecting our operational flexibility.
• The fair value of consideration paid in the Cornerstone acquisition totaled $42,008,000, including $37,845,000 for the line of credit. This change might impact future financial stability.
• Total revenue rose significantly from $279 million to $637 million, reflecting strong business growth.
• The Merger Agreement requires approval from Cyclo's stockholders, impacting the completion timeline of the Business Combination.
• Cornerstone incurred a net loss of $93.0 million from the acquisition date through July 31, 2024, impacting Rafael's consolidated financial results significantly.
• The purchase of additional equity interest increases the parent’s controlling interest in the subsidiary.
• The Company now owns a 37.5% equity interest in RP Finance LLC, which holds significant investments. This change could influence financial stability and investment strategies.
• The Company consolidated RP Finance as a variable interest entity, gaining control over its economic performance. This consolidation may lead to improved financial reporting and risk management.
• The company has updated its accounting standards codification from Section 323 to Section 505, reflecting changes in reporting practices.
• The Company reported a loss from discontinued operations improved from $(1,830) thousand to $(306) thousand, indicating better operational efficiency.
• Definition of shares after forfeiture now excludes shares issued under employee stock ownership plan (ESOP). This change clarifies share calculations for investors.
• The definition of fair value portion of investment securities now includes marketable securities and derivatives. This change might clarify valuation methods for investors.
• If the Business Combination is terminated due to a Cyclo Adverse Change Recommendation, Cyclo will pay Rafael $400,000 in cash.
• The company has updated its accounting standards codification, changing from 470 to 220. This change might result in improved compliance and reporting accuracy.
• The restructuring of Cornerstone included forgiveness of a line of credit valued at $37,845,000 and a promissory note of $2,663,000. This restructuring may enhance financial stability.
• The company’s long-term debt rose from $10 million to $210 million, raising concerns about future cash flow and repayment capabilities.
• The company now discloses a risk related to cybersecurity threats, which could lead to financial losses and reputational damage.
• The Portfolio Companies may face increased costs and delays due to ongoing COVID-19 impacts on clinical trials and operations.
• Basic and diluted loss per share attributable to common stockholders increased from $0.08 to $1.45. This change may impact investor sentiment and stock valuation.
• Total minimum future rental income from related parties is now $78,000, down from $946,000. This change might impact revenue projections significantly.
• The company has updated its accounting standards codification, changing from 3 to 5. This change might result in improved clarity in financial reporting.
• For the year ended July 31, 2024, one customer represented 51% of total revenue, indicating increased revenue concentration risk.
• The accounting standards reference changed from Section S99 - Paragraph 1A to Section S99 - Paragraph 1B, indicating updates in compliance requirements that could affect financial reporting.
• The Company raised $925,000 from third parties in exchange for 31.6% ownership of Rafael Medical Devices. This capital infusion may enhance operational capabilities and growth potential.
• The value of stock issued pursuant to acquisitions during the period is now detailed. This change might result in clearer financial assessments for investors.
• The value of stock issued pursuant to acquisitions during the period has increased from $1 billion to $1.5 billion, indicating a significant rise in acquisition activity.
• The definition of stock issued during the period has been expanded to include acquisitions. This change might enhance understanding of equity transactions.
• Ownership percentage of common stock increased from 31.50% to 34.00%. This change might result in greater influence over subsidiary decisions.
• The company reported a consolidated net loss of $65,003,000 for the year ended July 31, 2024, compared to a loss of $142,377,000 in the previous year. This improvement indicates better financial performance.
• The Portfolio Companies' reliance on third-party manufacturers exposes them to risks, including potential supply chain disruptions and quality control issues.
• The total revenue from discontinued operations decreased from $3,499 thousand to $249 thousand, reflecting a substantial decline in business activity.
• Cornerstone's second license agreement allows for royalties based on a low single-digit percentage of net sales, potentially affecting revenue projections significantly.
• Approximately 94% of the outstanding Series C Convertible Notes, totaling $15.5 million, participated in the Series C Convertible Notes Exchange, enhancing equity structure.
• The company added details on the impact of foreign currency translation adjustments on net income. This change might affect investor perception of currency risk.
• The Company adopted a current expected credit losses (CECL) model effective August 1, 2023, impacting how credit losses are estimated on available-for-sale debt securities.
• The net loss attributable to Rafael Holdings, Inc. decreased from $124,658 to $34,410, showing improved financial performance.
• The company added a definition for the amount of merger agreement incurred related costs, which could affect future financial reporting and investor confidence.
• The principal amount of the Cyclo Convertible Note III is $3 million, convertible into shares of Cyclo’s common stock.
• We may incur up to $250,000 in expenses related to the Merger, regardless of its completion, impacting our financial resources.
• The company has updated its risk factor regarding competition, noting increased competition in the market could affect market share and revenues.
• The definition of shares issued under share-based payment arrangements now excludes those under employee stock ownership plans. This change clarifies reporting and may affect financial metrics.
• The net loss from continuing operations attributable to common stockholders increased from $42,483,000 to $6,745,000 for the twelve months ended July 31, 2024. This change indicates significant operational challenges.
• The company clarified the definition of cash outflows for acquiring equity securities measured at fair value. This change might affect cash flow projections for investors.
• The Company recognized $2.5 million from a withdrawal of Hedge Fund Investments, impacting liquidity and investment strategy.
• The company disclosed a new accounting policy for revenue from contracts with customers, enhancing transparency in financial reporting.
• The company’s total current assets decreased from $108,347,000 to $72,502,000, reflecting a significant reduction in liquidity. This change may impact operational flexibility.
• The weighted average grant date fair value for shares granted decreased from $1.99 to $1.75. This change might impact future compensation expense calculations.
• The company received $825,000 as a deposit from third-party investors for membership units, indicating strong investor interest.
• The company added a risk related to reliance on key personnel, emphasizing potential disruptions if key employees leave.
• The company has added details regarding the definition of realized gains or losses on investments, enhancing transparency in financial reporting.
• The unrealized gain on investments increased from $1,191 to $2,663, suggesting better investment performance.
• The Company has determined that RP Finance and Day Three are VIEs, impacting consolidation and financial reporting.
• The exercise price of warrants changed from $1.25 to $0.71, potentially affecting future capital raising strategies.
• Cybersecurity risks are increasing, with potential disruptions to our operations and significant harm to our reputation and financial condition.
• Rafael recognized a gain of $30.6 million related to the fair value of Cornerstone Common Stock received in the Cornerstone Acquisition, impacting financial performance positively.
• The Portfolio Companies may not receive patent term extensions, potentially reducing marketing exclusivity for product candidates and device candidates.
• The valuation allowance for deferred tax assets increased from $49,096 thousand to $71,275 thousand, indicating potential future tax liabilities.
• The Company’s infusion technology revenue is derived from Day Three’s Unlokt technology, recognized over time as performance obligations are satisfied.
• The percentage of ownership interest in CS Pharma Holdings remains at 90.00%, indicating stable control over this subsidiary.
• The definition of stock issued under share-based payment arrangements now explicitly excludes shares issued under employee stock ownership plans (ESOP), clarifying accounting practices.
• The company’s accumulated deficit increased to $(201,743,000) from $(167,333,000), indicating growing financial challenges that could concern investors.
• The Portfolio Companies may be subject to state laws that complicate compliance efforts, increasing operational risks and costs.
• Interest income rose from $2,383 to $3,253, indicating improved cash management and investment returns.
• The company disclosed a risk regarding fluctuations in stock prices, which could affect investor confidence and capital raising efforts.
• The End Date for the Merger Agreement has been extended to December 31, 2024, allowing more time for completion.
• The disclosure now includes the number of shares issued during the period as a result of stock splits. This change might impact the analysis of share structure.
• The company has revised its disclosure practices related to research and development expenses, aligning with updated accounting standards.
• The company recognized a realized gain on investments of $1,772,000, compared to a loss of $(45,000) in the previous year. This positive shift may enhance investor confidence.
• The aggregate fair value of investments remains at $10,745,629, reflecting consistent valuation in the current market.